5 July 2019 - Dacomitinib has been recommended as a first-line treatment option for people with a type of non-small-cell lung cancer, in new NICE guidance.
This once-a-day pill will be available on the NHS for adults with locally advanced or metastatic non-small-cell lung cancer, who have tested positive for the epidermal growth factor receptor mutation.
This is a change from the committee’s initial decision which found dacomitinib to not be a cost-effective use of NHS resources.